Figure 1.
Medication use at the first seven visits of the CKiD study. Medication use increased per visit as follows: active vitamin D, 7.5% (P<0.001); iron supplement, 3.9% (P=0.004); alkali therapy, 4.8% (P=0.002); phosphate binder, 7.9% (P<0.001); nutritional vitamin D, 17.6% (P<0.001); ESA, 2.6% (P=0.34); and rhGH, 3.1% (P=0.32). CKiD, Chronic Kidney Disease in Children; ESA, erythrocyte-stimulating agent; rhGH, recombinant human growth hormone.